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Abstract
Introduction: In Bangalore, new HIV infections of female sex workers and men who have sex with men continue to occur,
despite high condom use. Pre-exposure prophylaxis (PrEP) has high anti-HIV efficacy for men who have sex with men. PrEP
demonstration projects are underway amongst Indian female sex workers. We estimated the impact and efficiency of prioritizing
PrEP to female sex workers and/or men who have sex with men in Bangalore.
Methods: A mathematical model of HIV transmission and treatment for female sex workers, clients, men who have sex with men
and low-risk groups was parameterized and fitted to Bangalore data. The proportion of transmission attributable (population
attributable fraction) to commercial sex and sex between men was calculated. PrEP impact (infections averted, life-years gained)
and efficiency (life-years gained/infections averted per 100 person-years on PrEP) were estimated for different levels of PrEP
adherence, coverage and prioritization strategies (female sex workers, high-risk men who have sex with men, both female sex
workers and high-risk men who have sex with men, or female sex workers with lower condom use), under current conditions
and in a scenario with lower baseline condom use amongst key populations.
Results: Population attributable fractions for commercial sex and sex between men have declined over time, and they are
predicted to account for 19% of all new infections between 2016 and 2025. PrEP could prevent a substantial proportion of
infections amongst female sex workers and men who have sex with men in this setting (23%/27% over 5/10 years, with 60%
coverage and 50% adherence), which could avert 2.9%/4.3% of infections over 5/10 years in the whole Bangalore population.
Impact and efficiency in the whole population was greater if female sex workers were prioritized. Efficiency increased, but
impact decreased, if only female sex workers with lower condom use were given PrEP. Greater impact and efficiency was
predicted for the scenario with lower condom use.
Conclusions: PrEP could be beneficial for female sex workers and men who have sex with men in Bangalore, and give some
benefits in the general population, especially in similar settings with lower condom use levels.
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Introduction
India has a concentrated HIV epidemic. In Bangalore, as
elsewhere in southern India, the highest HIV levels are found
amongst female sex workers (FSWs; 8.0% prevalence 2009),
FSWs’ commercial clients (2.4%, 2007), and men who have
sex with men (MSM; 16.5%, 2009) [14]. HIV prevalence
among the general population is much lower (0.75% amongst
women attending antenatal care (ANC) in 2012) [5]. Previous
modelling suggests that most HIV transmission in southern
India is driven by commercial sex [6].
Following the Avahan intervention, which promoted con-
dom use for FSWs and MSM [7], reported condom use
increased. In 2006, 74% of MSM reported using condoms
consistently with casual male sex partners, and in 2011, 90%
of FSWs reported using condoms consistently with new
commercial clients [4,8]. However, FSWs report much lower
condom use with non-commercial partners [9].
Between surveys conducted in 2006 and 2009, HIV
prevalence amongst FSWs in Bangalore fell, consistent with
reported increases in condom use [7], but remained level
between 2009 and 2011 [10]. HIV prevalence amongst MSM
remained similar between 2006 and 2009 [11].
Oral daily pre-exposure prophylaxis (PrEP), which involves
HIV-negative individuals taking a daily tablet containing
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tenofovir or tenofovir/emtricitabine, has been shown to
reduce the risk of HIV acquisition for MSM [1214] and
heterosexuals, providedmedication is taken regularly [1518].
The iPrEx trial found an overall reduction in HIV acquisition
amongst MSM of 44% in the entire cohort, rising to 92%
amongst those with detectable drug in their blood [12], while
the IPERGAY and PROUD trials both reported an overall 86%
reduction in HIV acquisition amongst MSM [13,14]. Trials
amongst heterosexuals found HIV risk reductions between
0 and 75%, with efficacy strongly related to PrEP adherence
[19]; in the Partners PrEP study, an efficacy of 90% for
tenofovir/emtricitabine was estimated amongst those with
detectable drug in their blood [15].
While reported condom use by FSWs and MSM is high, new
infections continue to occur in many Indian settings, and there
is interest in finding additional interventions which might
reduce HIV incidence amongst these populations to low levels.
PrEP is a promising candidate which, unlike condoms, can be
used without a partner’s knowledge. A PrEP demonstration
project is underway amongst FSWs in two Indian cities,
Mysore and Kolkata [20]. Because of this, and the demon-
strated efficacy of PrEP for MSM, the potential impact of PrEP
for these groups in India is of great interest. Here, we used
mathematical modelling to estimate the contribution made by
these key populations to the HIV epidemic in Bangalore, the
impact of offering PrEP to FSWs and/orMSM in Bangalore, and
the population-level impact and efficiency of different PrEP
prioritization strategies.
Methods
Model
We extended a deterministic, compartmental model of HIV
transmission amongstMSM in Bangalore [21] to include FSWs,
FSW clients, former MSM, FSWs and clients, and low-risk males
and females. Individuals enter the model on sexual debut. The
model divides HIV-negatives by PrEP status, and HIV-positives
by infection stage (acute, CD4 500, 350 to 500, 200 to 350,
B200 cells/ml, pre-AIDS, AIDS) and engagement with HIV care
and treatment (never testing/testing but not in care/in pre-
anti-retroviral therapy (ART) care/on ART/no longer on ART).
ART is initiated following testing and pre-ART care, or after
becoming symptomatic (CD4B200 cells/ml).
MSM are divided into three groups, related to the role
taken in sex with men: kothi and hijra (usually receptive),
panthi and bisexual (usually insertive) and double deckers
(both insertive and receptive). Kothi/hijra and double deckers
are collectively called ‘‘high-risk’’ MSM (HR-MSM).
FSWs are divided by reported condom use with new clients
(‘‘always’’ (high-condom) versus ‘‘often/sometimes/never’’
(low-condom)), with women recruited into the high-condom
group over time reflecting historical changes in condom use.
Individuals leave the population due to natural or AIDS-
relatedmortality, and those in key populations can leave them,
entering the former MSM/FSW/client groups. The modelled
population grows over time, in line with observed Bangalore
population growth.
Those on ART progress through the same HIV infection
stages as other HIV-positive people, but more slowly. Tempor-
ary cessation of ART, with rapid ART re-initiation, is not
explicitly modelled. Long-term dropouts from ART, who are
not rapidly re-initiated, are assumed to only seek treatment
when they become symptomatic; in our model this is
approximated as reaching CD4B200 cells/ml.
HIV was seeded in the model amongst MSM, FSWs and
clients in 1986 [22] (the earliest year with HIV prevalence data
for southern India), and the epidemic was simulated until
2037.
Condom use and rates of HIV testing and linkage into care
were assumed to increase linearly over time in line with data,
remaining constant after the latest data estimate (Supple-
mentary Figure 2).
See Supplementary File for further model details, schematic
(Supplementary Figure 1) and equations.
Parameterization and fitting
HIV prevalence data and behavioural data used to para-
meterize the model came from integrated behavioural and
biological assessments [23], conducted amongst FSWs, MSM
and clients in Bangalore at two or three time points between
2006 and 2012. Additional behavioural data were obtained
from special behavioural surveys, conducted amongst FSWs
and MSM in Bangalore in 2006 [24]. Condom use trends were
estimated using data on current levels and duration of
consistent condom use [25] and trends in HIV testing rates
were estimated by fitting linear trend-lines to self-reported
testing rates in different surveys [4]. Condom use in regular
(non-commercial) partnerships was based upon levels re-
ported in such partnerships by FSWs, clients and MSM [4].
Population sizes were estimated from MSM and FSW
mapping surveys [26], population-based surveys from neigh-
bouring districts [27], and district census estimates.
Biological parameters and the efficacy of condoms and ART
for reducing HIV transmission were obtained from published
literature.
Rates of linkage to HIV care, numbers of adults on ART (2007
to 2012) and ART coverage (20072009) were estimated from
state-level data [2830].
Selected parameters are given in Table 1, details of all model
parameters in Supplementary Table 1 (Supplementary File).
The model was fitted to HIV prevalence and ART cover-
age in two stages within a Bayesian framework [31] (see
Supplementary File).
Analysis
Baseline prevalence and incidence
Overall HIV prevalence was compared with Bangalore ANC
and Mysore data. The time of HIV elimination (B1 new
infection/1000 person-years) was estimated.
Population attributable fraction
The population attributable fraction (PAF) quantifies the
contribution of a particular risk factor to cases of disease. We
used PAF to understand the factors driving HIV transmission,
which is crucial for designing effective prevention interven-
tions. The model was used to estimate the PAF of commercial
sex, sex between men and regular partnerships to the overall
HIV epidemic, and to the FSW and MSM epidemics, over
sequential 10-year periods from 1986. The PAF was estimated
by determining the relative reduction in the number of
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HIV infections over each 10 year period if the transmission
probability for commercial sex, sex between men or regular
partnerships was set to 0 over that period.
PrEP intervention scenarios
PrEP interventions were modelled commencing January
2017. HIV-negative individuals were recruited onto PrEP at
a constant rate, and stopped taking PrEP if they acquired HIV
infection or dropped out (assumed 20% annually). PrEP was
offered only to current MSM or FSW, those leaving these
groups were assumed to stop taking PrEP. Drug resistance
was not included. PrEP efficacy was assumed to be 93%
under perfect adherence (between the efficacy estimates for
daily dosing from the iPrEx and Partners PrEP trials [32,33]).
PrEP coverage for prioritized groups was calibrated to reach
20 or 60% coverage of HIV-negatives after five years.
Table 1. Selected sexual behaviour and intervention parameters
Parameter Value Range
Sexual behaviour
Commercial sex acts per year for FSW 384.0 359.0410.0
Commercial sex acts per year for non-MSM clients 19.6 17.921.4
MSM sex partners per year for kothi/hijra 130.5 93.0168.0
MSM sex partners per year for double deckers 69.5 53.086.0
MSM sex partners per year for panthi/bisexuals 49.0 2.096.0
For those with a regular partner, number of vaginal sex acts per year 108.4 90.8127.6
Condom use
% of commercial sex acts in which condom used in 2011 90.0 87.392.7
% of anal sex acts between MSM in which condom used in 2007 70.5 63.777.2
% of sex acts in which condom used in regular partnerships 16.1 5.127.0
HIV testing
% of MSM testing for HIV annually after 2009 58 5066
% of FSW testing for HIV annually after 2011 90 8792
% of clients, former MSM, former FSW, low-risk population testing for HIV annually after 2007 11 714
PrEP intervention
Proportion of MSM offered and initiating PrEP upon testing negative for HIV to achieve required
PrEP coverage
20%: 0.105/ti,Max
60%: 0.59/ti,Max
a
fixed
Proportion of FSW offered and initiating PrEP upon testing negative for HIV to achieve required
PrEP coverage
20%: 0.17
60%: 1.0
fixed
Rate of PrEP dropout, all groups, per person per year 0.2 fixed
Pre-ART care linkage and dropout
Proportion linking to pre-ART care, all groups, 2011 onwards 0.8 0.70.9
Ratio of dropout from pre-ART care relative ART dropout rate 2 13
ART
Rate at which those in pre-ART care, in HIV stage i, initiate ART, per year Pre-2004, 0 all i
20042011, 2 if
CD4B200, 0 otherwise
2011 onwards, 2 if
CD4B350, 0 otherwise
fixed
Rate of initiating ART per year due to symptoms in AIDS stage Pre-2004, 0
2004 onwards, 1 02
Relative rate of initiating ART due to symptoms in pre-AIDS stage relative to AIDS stage 0.11
Relative rate of initiating ART due to symptoms with CD4B200 relative to those in pre-AIDS stage 0.11
Rate of ART dropout, per year 0.04 0.010.07
Factor by which HIV progression rates are multiplied when on vs off ART 1/3 fixed
Intervention efficacies in reducing HIV transmission risk
Per-sex-act efficacy of ART in anal or vaginal sex (%) 92 26100
Per-sex-act efficacy of condoms in vaginal sex (%) 80 6694
Per-sex-act efficacy of condoms in anal sex (%) 6194
Per-sex-act efficacy of PrEP (%) 93 fixed
For sources and details of all other parameters, see Supplementary Table 1.
ati,Max% of MSM testing for HIV annually after 2009.
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Different adherence scenarios were explored: 30, 50 or 75%
adherence, as found in different trials [12,18,33]. Overall
PrEP effectiveness was calculated as the product of the
assumed efficacy and adherence; this relationship approx-
imates that seen in the iPrEx and Partners PrEP trials, with
adherence measured by detectable drug in blood [34]
(effectiveness23%, 47%, 70% for 30%, 50%, 75% adher-
ence scenarios, respectively). Four prioritization scenarios
were examined, with PrEP prioritized to all FSWs; HR-MSM;
FSWs and HR-MSM; or only low-condom FSWs.
We assessed the effect of a hypothetical change in ART
eligibility to all HIV-positives (regardless of CD4 count)
starting in 2017.
The effect of imperfect prioritization of PrEP for FSWs was
investigated by comparing scenarios where the same amount
of PrEP (sufficient for 60% coverage of low-condom FSWs)
was distributed amongst low-condom FSWs, all FSWs or high-
condom FSWs.
We assessed the possible impact of condom migration by
comparing the impact of PrEP when condom use is reduced
amongst those using PrEP with the situation where condom
use is maintained.
Finally, we examined a scenario with lower condom use
amongst key populations to give insights into the possible
impact of PrEP in other lower condom use settings. In this
second scenario, condom use by FSW and MSM remained
constant after 2003 (Supplementary Figures 2 and 3).
Outcome measures
Impact within the prioritized groups and in the whole
Bangalore population was measured as cumulative number
and percentage of infections averted (IA) over five or ten years
and life-years gained (LYG) over 20 years. The longer time-
frame for LYG is used because of the delay in impact on
mortality following the prevention of an infection. Efficiency
was defined as LYG or IA per 100 person-years on PrEP. Impacts
were not discounted over time.
Results
Baseline prevalence and incidence trends
Of one million parameter sets, 115 fitted HIV prevalence and
ART coverage data. Most fits suggested declining FSW and
client HIV prevalence, in line with data (Supplementary Figure
4a and b), but predicted more rapid HIV prevalence decline
amongst MSM than data suggests (Supplementary Figure
4ce). Although the model was not fitted to overall popula-
tion HIV prevalence (unavailable for Bangalore), prevalence
trends were similar to data for nearbyMysore [35], and female
prevalence was similar, although sometimes higher, than
Bangalore ANC data [36] (Supplementary Figure 4fh).
For most model fits (72%), overall HIV incidence was
predicted to decline below 1 infection/1000 person-years by
2037 without PrEP, with 50% reaching this threshold by 2015,
but 19% of fits predicted that overall incidence would be rising
in 2037.
Population attributable fractions
Between 1986 and 1995, a median 68% of new HIV infections
(95% credible interval (CrI) 55 to 84%) were estimated to be
attributable to commercial sex, and 27% (13 to 54%) to sex
between men, together accounting for 85% (72 to 95%) of
new infections (Supplementary Figure 5a). These PAFs
declined over time, as condom use amongst key populations
and HIV prevalence in the rest of the population increased;
we predicted that between 2016 and 2025, 19% (12 to 20%)
of new infections would be attributable to commercial sex or
MSM. The PAF for regular partnerships involving current
MSM, FSWs and clients declined more slowly, from 51%
(1986 to 1995) to 38% (2016 to 2025; Supplementary
Figure 5b), while the PAF for regular partnerships involving
former MSM, FSWs and clients increased from 17 to 60%.
Few (B10%) new infections were attributable to partnerships
between low-risk men and women. FSWs and (particularly)
MSM are estimated to have had a modest effect upon each
other’s HIV epidemics, and are predicted to account for less
than 10% of each other’s new HIV infections between 2016
and 2025 (Supplementary Figure 5c).
In Scenario 2, where condom use plateaued after 2003,
higher PAFs for commercial sex and sex between men were
predicted post-2003, with 36% of new infections between
2016 and 2025 being attributable to either commercial sex or
sex between men (Supplementary Figure 5d), 49% to regular
partnerships involving former MSM, FSWs or clients (Supple-
mentary Figure 5e), and 19% of new MSM infections attrib-
utable to FSW commercial sex (Supplementary Figure 5f).
PrEP impact: key populations
PrEP coverage time-trends are shown in Supplementary
Figure 6.
A PrEP intervention prioritized to and reaching 60% of all
HIV-negative FSWs after five years, with 50% PrEP adherence
(47% effectiveness), averted 23% of FSWs infections (22 to
24%) over five years (Figure 1a). Similar results were seen
prioritizing HR-MSM (Figure 1b). Five-year impact varied
linearly with assumed adherence (Figure 1a and b) and
coverage.
Impact increased slightly over time, with 26%/29% of FSW/
HR-MSM infections being prevented after 10 years for 60%
coverage and 50% adherence (data not shown).
PrEP gave sustained incidence reductions among FSWs and
MSM  after five years, an intervention reaching 60% of HR-
MSM and FSWs reduced incidence amongst FSWs by 19, 31
or 45% with 30, 50 or 75% adherence, respectively, with
similar reductions among HR-MSM (Supplementary Figure 7).
Figure 2 show the combinations of adherence and cover-
age required to meet different impact targets. Reaching 60%
of FSWs, 56 or 93% adherence was required to prevent 30 or
50% of FSW infections after 10 years, respectively (Figure 2a).
To reach these targets after only five years, higher adherence
(64%) was required to prevent 30% of FSWs infections with
60% coverage, and coverage had to exceed 61% to prevent
50% of FSW infections. Slightly lower coverage and adher-
ence levels were required to reach these targets for HR-MSM
(Figure 2b).
PrEP impact: overall Bangalore population
The proportion of IA in the whole Bangalore population after
five years was low, but greater with FSW prioritization (1.8%
(0.93.1%), for 50% adherence and 60% coverage) than HR-
MSM prioritization (1.2% (0.52.9%)). The proportion of IA
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when both groups were prioritized (2.9%) was almost additive
(Figure 3). Impact increased by 50% after 10 years (4.3%
prioritizing FSWHR-MSM). Prioritizing only lower-condom
FSWs gave substantially lower population-level impact (Figure 3).
With FSW prioritization, large numbers of infections were
prevented amongst FSWs, clients and other groups, whereas
most infections were prevented amongst MSM with HR-MSM
prioritization (Supplementary Figure 8).
HIV elimination (incidence 51 infection/1000 person-
years) was slightly more likely to occur with PrEP interven-
tions in place, with elimination by 2037 for 79% of model fits,
and only 15% of model fits predicting increasing incidence in
2037.
PrEP efficiency
More life-years were gained in the whole population with
FSW compared with HR-MSM PrEP prioritization (Figure 4a).
PrEP efficiency was greatest when low-condom FSWs were
prioritized (3.7 LYG/100py PrEP after 20 years), followed by
all FSWs (2.2 LYG/100py PrEP), with lower efficiency when
HR-MSM were prioritized (0.7 LYG/100py PrEP; Figure 4b).
Similar patterns were seen with IA: efficiency was 2.2, 1.4
and 0.6 IA/100py PrEP over five years prioritizing low-
condom FSWs, all FSWs or HR-MSM (Figure 4c).
Changes to ART eligibility
PrEP impact among the prioritized group was not affected by
ART eligibility changes; impact and efficiency in the whole
population declined slightly with expanded ART eligibility
from 2017 (Supplementary Figure 9).
Imperfect prioritization and condom migration
The proportion of IA and PrEP efficiency were roughly halved
when the same amount of PrEP was distributed amongst all
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Figure 2. Coverage and adherence required to meet impact targets.
Combinations of coverage (after five years) and adherence required to meet impact targets of 30 or 50% of infections averted over five or ten years
amongst (a) FSW and (b) HR-MSM, when that group is prioritized with a PrEP intervention. Results are shown for the best-fit parameter set.
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Figure 1. Percentage of infections averted amongst FSW and HR-MSM for PrEP interventions prioritizing each population.
Percentage of infections averted amongst (a) all FSWs and (b) HR-MSM over five years, for PrEP interventions prioritizing this population, with
PrEP adherence and coverage shown. Bar shows median and error bars are 95% credible interval across 115 parameter sets. Credible intervals
give the 2.5th and 97.5th percentiles of estimates across all parameter combinations.
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FSWs or high-condom FSWs, compared with low-condom
FSWs (Figure 5).
To completely negate the beneficial impact of PrEP, a 50%
relative reduction in condom use by those individuals using
PrEP was needed when prioritizing PrEP to all FSWs, compared
with a 90% relative reduction in condom use when PrEP was
prioritized to HR-MSM or low-condom FSWs (Supplementary
Figure 10).
Scenario with lower baseline condom use
When lower levels of condom use were assumed post-2003
(Scenario 2), the overall impact and efficiency of PrEP in the
whole Bangalore population were predicted to be greater
than in our original scenario, particularly when FSWs were
prioritized (Figure 6). The percentage of IA in the whole
population after five years was 26% greater in the lower
condom use scenario compared to the baseline scenario when
prioritizing HR-MSM, and 2.1-fold greater when prioritizing
FSWs; efficiency after 20 years was 2.3-fold and 4.2-fold
greater when prioritizing HR-MSM or FSWs, respectively.
Discussion
We found that PrEP prioritized to FSWs or HR-MSM in
Bangalore could substantially reduce HIV incidence amongst
the prioritized group, preventing 22 to 25% of infections over
0%
1%
2%
3%
4%
5%
6%
7%
8%
HR-MSM HR-MSM
+FSW
FSW low-
condom
use FSW
%
 in
fe
ct
io
ns
 a
ve
rte
d 
wh
ol
e
po
pu
la
tio
n
Target group
5 yrs 10 yrs 5 yrs 10 yrs 5 yrs 10 yrs 5 yrs 10 yrs
Figure 3. Percentage of infections averted in the whole Bangalore
population.
Percentage of infections averted in the whole Bangalore population
over five and ten years, for an intervention with 50% adherence and
60% coverage of the priority group (as shown). Bar shows median
and error bars are 95% credible interval across 115 parameter sets.
Credible intervals give the 2.5th and 97.5th percentiles of estimates
across all parameter combinations.
0
1
2
3
4
5
6
IA
 p
er
 1
00
py
 o
n 
Pr
EP
Target group
(c)
HR-MSM FSW HR-MSM
+FSW
low-
condom
use FSW
0
4,000
8,000
12,000
16,000
HR-MSM FSW HR-MSM
+FSW
low-
condom
use FSW
LY
G
Target group
(a)
HR-MSM FSW HR-MSM
+FSW
low-
condom
use FSW
0
2
4
6
8
10
12
LY
G
 p
er
 1
00
py
 o
n 
Pr
EP
Target group
(b)
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the first five years of an intervention achieving 60% PrEP
coverage of the prioritized group with 50% adherence.
However, we predict a much smaller impact in the whole
Bangalore population, due to higher levels of HIV transmis-
sion now occurring outside these high-risk groups. This is
reflected in the lower PAF of commercial sex and sex
between men predicted after 2016, and higher PAF for
regular partnerships. Other modelling studies have also
suggested that the PAF for commercial sex has declined
over time in West/Central Africa [37,38] and southern India
[6], as condom use in commercial sex increased and greater
HIV transmission occurred outside key populations.
Sixty percent coverage of key populations requires high
PrEP uptake rates, which may be feasible given high
willingness to use PrEP among Indian MSM and FSWs [39].
A greater population-level impact was seen if FSWs were
prioritized rather than HR-MSM, due to FSWs and their
clients having more sexual interactions with the low-risk
population than MSM, so more infections are averted
outside key populations. We saw an almost additive effect
of prioritizing both FSWs and HR-MSM together, due to the
small overlap in their sexual networks as evidenced by the
small degree to which FSWs contribute to MSM HIV
transmission and vice versa.
Due to the greater number of infections prevented outside
the prioritized population when FSWs were given PrEP rather
than HR-MSM, the efficiency of PrEP was greater when
prioritizing FSWs, although still rather low. The most efficient
intervention  prioritizing FSWs with lower condom use 
only achieved 4 LYG/100 person-years on PrEP over 20 years,
which is unlikely to be cost-effective, given the high costs of
PrEP interventions (cheapest estimate 95 US$/person/year
[40], giving ]US$2375/LYG). Another study modelling PrEP
for FSWs in South India also found low efficiency, attributed
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Figure 5. PrEP impact and efficiency in the whole population for different FSW prioritization scenarios.
(a) % infections averted in the whole population after five years and (b) PrEP efficiency (life-years gained per 100 person-years on PrEP)
measured in the whole population over 20 years, for the same total number of person-years on PrEP for different FSW prioritization scenarios.
Bars show median and error bars are 95% credible interval across 115 parameter sets.
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to high levels of FSW condom use [41]. Another modelling
study predicted low impact of PrEP for FSWs using condoms
frequently in commercial sex [42]. HIV prevention cost-
effectiveness studies have suggested that it is most cost-
effective to first implement behaviour change interventions
and early ART, with the subsequent addition of PrEP not
always being cost-effective [4345]. However, as local epi-
demics head towards elimination, it may become necessary
to shift the focus from cost-effectiveness thresholds towards
achieving elimination efficiently.
The most efficient PrEP strategy in this setting was to only
give PrEP to FSWs with lower condom use. However, due to
the small size of this group, this strategy would only give a
small impact on the overall epidemic. Studies estimating
the cost-effectiveness of PrEP for MSM in Australia [46] and
Peru [47] have similarly found that, although it is more cost-
effective, the prioritization of small, higher-risk groups for
PrEP has limited population-level impact.
We predicted that the Bangalore HIV epidemic is close to
elimination without PrEP, using a threshold of population
incidence below 1/1000 person-years [48], and that, while
PrEP for FSWs or MSM gives large incidence reductions among
the prioritized population, it only slightly increases the like-
lihood and speed of reaching elimination.We assume that high
levels of condom use are maintained, which will be crucial
for achieving elimination. Future analyses should investigate
whether elimination could be accelerated by additionally
intervening among clients or regular partners [49].
We predicted that expanded ART eligibility would only
slightly reduce the impact and efficiency of PrEP interven-
tions, perhaps due to low HIV testing rates amongst the
general population, where most new infections occur.
We predicted that large reductions in condom use (B50%
for FSW, B90% for MSM) could occur amongst individuals
taking PrEP (with 50% adherence) without offsetting the full
benefits of PrEP, and so although condom use should continue
to be promoted, condom migration is unlikely to negate the
effects of PrEP in this setting. This agrees with MSM studies
[46,47], which suggested 80% reduction in condom use by
MSM on PrEP would be needed to cancel out PrEP benefits.
However, a study among FSWs in India suggested that a 15%
reduction in condom use by FSWs taking PrEP could negate the
impact of PrEP [41].
Finally, we predicted greater impact and efficiency of PrEP
in settings with lower condom use and higher HIV prevalence,
suggesting that prioritized PrEP could be valuable in settings
where condom use remains persistently low despite efforts to
scale it up; this agrees with earlier modelling studies of topical
PrEP [50].
Strengths and limitations
Our model made use of extensive setting-specific data from
key populations, which should improve the reliability of our
results; however, the data may not be fully representative of
local key populations, since the sampling methods used were
designed to capture higher-risk MSM, and participation
rates were relatively low, particularly among clients. If the
individuals sampled were at higher risk than the wider key
population groups, we may have overestimated HIV incidence
and PrEP impact. Our fitting method ensured that consider-
able uncertainty in many of the model parameters was taken
into account, and so our findings should be robust to this
uncertainty. In the absence of data on PrEP retention, we
assumed 20% annual dropout; lower retention would reduce
the PrEP coverage that can be achieved, reducing impact. Our
model did not stratify the FSW and MSM populations by
sexual activity, and so we were not able to assess the possible
impact of prioritizing PrEP to individuals with higher levels of
sexual activity, which could improve PrEP efficiency. Cost-
effectiveness could not be assessed as cost data was not
included.
Conclusions
PrEP could have a substantial impact upon HIV incidence
amongst FSWs and MSM in Bangalore, but is likely to have a
minor impact at the general population level. Prioritizing PrEP
to FSWs with sub-optimal condom use will improve efficiency
but reduce overall population-level impact in this setting. In
other settings with lower levels of condom use amongst key
populations, the provision of PrEP to these high-risk popula-
tions may result in a greater general-population impact.
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